{{Rsnum
|rsid=11203995
|Gene=PSD3
|Chromosome=8
|position=18771863
|Orientation=plus
|GMAF=0.3324
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=PSD3
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 19.5 | 43.4 | 37.2
| HCB | 85.4 | 14.6 | 0.0
| JPT | 88.5 | 11.5 | 0.0
| YRI | 76.9 | 21.8 | 1.4
| ASW | 62.5 | 33.9 | 3.6
| CHB | 85.4 | 14.6 | 0.0
| CHD | 88.9 | 11.1 | 0.0
| GIH | 42.6 | 41.6 | 15.8
| LWK | 85.5 | 14.5 | 0.0
| MEX | 37.9 | 44.8 | 17.2
| MKK | 54.5 | 38.5 | 7.1
| TSI | 12.9 | 40.6 | 46.5
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs11203995
|Name_s=
|Gene_s=PSD3
|Feature=
|Evidence=PubMed ID:19176441
|Annotation=This variant is associated with end-of-induction minimal risidual disease (MRD) in childhood acute lymphoblastic leukemia (ALL) from 2 independent cohorts (GWAS result). Risk Allele: C, MAF= 0.49, combined P value= 4.30E-04.
|Drugs=
|Drug Classes=
|Diseases=Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymphoma
|Curation Level=Curated
|PharmGKB Accession ID=PA162470241
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs11203995
|overall_frequency_n=41
|overall_frequency_d=128
|overall_frequency=0.320312
|n_genomes=26
|n_genomes_annotated=0
|n_haplomes=33
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}